Patient‐Derived Organoids Can Guide Personalized‐Therapies for Patients with Advanced Breast Cancer. Issue 22 (4th October 2021)

• Record Type: Journal Article
• Authors: Chen, Ping; Zhang, Xu; Ding, Renbo; Yang, Linglin; Lyu, Xueying; Zeng, Jianming; Lei, Josh Haipeng; Wang, Lijian; Bi, Jiong; Shao, Nan; Shu, Ditian; Wu, Bin; Wu, Jingbo; Yang, Zhihui; Wang, Haiyan; Wang, Biqiong; Xiong, Kang; Lu, Yun; Fu, Shaozhi; Choi, Tak Kan; Lon, Ng Wai; Zhang, Aiping; Tang, Dongyang; Quan, Yingyao; Meng, Ya; Miao, Kai; Sun, Heng; Zhao, Ming; Bao, Jiaolin; Zhang, Lei; Xu, Xiaoling; Shi, Yanxia; Lin, Ying; Deng, Chuxia;
• Is Part Of: Advanced science. Volume 8:Issue 22(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-10-04
• Subjects: advanced breast cancer -- drug screening -- patient‐derived organoids -- personalized therapy; Science -- Periodicals; 505
• DOI: 10.1002/advs.202101176
• Languages: English
• ISSNs: 2198-3844

Abstract

Abstract: Most breast cancers at an advanced stage exhibit an aggressive nature, and there is a lack of effective anticancer options. Herein, the development of patient‐derived organoids (PDOs) is described as a real‐time platform to explore the feasibility of tailored treatment for refractory breast cancers. PDOs are successfully generated from breast cancer tissues, including heavily treated specimens. The microtubule‐targeting drug‐sensitive response signatures of PDOs predict improved distant relapse‐free survival for invasive breast cancers treated with adjuvant chemotherapy. It is further demonstrated that PDO pharmaco‐phenotyping reflects the previous treatment responses of the corresponding patients. Finally, as clinical case studies, all patients who receive at least one drug predicate to be sensitive by PDOs achieve good responses. Altogether, the PDO model is developed as an effective platform for evaluating patient‐specific drug sensitivity in vitro, which can guide personal treatment decisions for breast cancer patients at terminal stage. Abstract : Personalized therapies are urgently needed for patients with advanced breast cancers. Patient‐derived organoids (PDOs) can be generated from breast cancer tissues for the identification of anticancer drugs with high efficacy. PDO pharmaco‐phenotyping can not only reflect the previous treatment responses of patients, but also serve as an in‐time platform to guide tailored therapy for the refractory disease.